Research & Development
Discover next generation oncology therapeutics by full human antibody mRNA display technology
Innovation and execution are the core value of the company. We are striving to advance next generation therapeutics for the benefits of cancer patients.
ELPIS IS DEVELOPING A PIPELINE THAT INCLUDES BISPECIFIC AND MULTI-FUNCTIONAL ANTIBODIES
Elpis takes advantage of full human antibody mRNA display technology to enable rapidly screen and discover target specific therapeutic antibody. Individual antibody can be further engineered to generate bispecific or multi-functional modality aiming for the treatment of variety of tumors, especially the ones are no-responsive or resistant to existing medicines.
ELPIS IS ALSO DEVELOPING A PIPELINE OF NOVEL CAR-T THERAPEUTICS THAT TAKE ADVANTAGE OF ANTIBODIES DISCOVERED THROUGH OUR MRNA DISPLAY TECHNOLOGY
Chimeric antigen receptors (CARs) T-cells, are T-cells that are engineered cells with tumor cell receptor recognizing antibody to enable a specific activation to target cancer cells. CAR-T cells with an single tumor cell receptor binding antibody could results in relapse or recurrence of cancer patient after treatment. We are developing next generation CAR-T therapeutics by targeting dual or multi-tumor specific/associated antigens to significantly improve the response and duration of CAR-T treatment against hematopoietic malignancy and solid tumors.